Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021 | Clinical Pharmacy and Pharmacology | JAMA
Based on the Vaccine Adverse Event Reporting System, this article reports on the prevalence of presumptive Guillain-Barré syndrome among recipients of the Ad26.
Source: jamanetwork.com